NASDAQ : ACAD
ACADIA Pharmaceuticals Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 20.59 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 3.55B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 3.55B |
| Enterprise Value | 2.67B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 172.31M |
| Shares Outstanding | 172.31M |
| Shares Change (YoY) | +2.98% |
| Shares Change (QoQ) | +0.08% |
| Owned by Insiders (%) | 0.55% |
| Owned by Institutions (%) | 74.95% |
| Float | 128.35M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 9.33 |
| Forward PE | 26.16 |
| PS Ratio | 3.12 |
| Forward PS | 2.53 |
| PB Ratio | 2.71 |
| P/TBV Ratio | 2.95 |
| P/FCF Ratio | 24.36 |
| P/OCF Ratio | 22.13 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 7.00 |
| EV / Sales | 2.34 |
| EV / EBITDA | 27.09 |
| EV / EBIT | 30.86 |
| EV / FCF | 18.30 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.39 |
| Quick Ratio | 3.11 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | 0.66 |
| Debt / FCF | 0.51 |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 35.74% |
| Return on Assets (ROA) | 3.64% |
| Return on Invested Capital (ROIC) | 19.82% |
| Return on Capital Employed (ROCE) | 6.25% |
| Weighted Average Cost of Capital (WACC) | 8.93% |
| Revenue Per Employee | $1.43M |
| Profits Per Employee | $476,797 |
| Employee Count | 798 |
| Asset Turnover | 0.77 |
| Inventory Turnover | 14.77 |
Taxes
| Measure | Value |
|---|
| Income Tax | -259.12M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.89 |
| 52-Week Price Change | -8.61% |
| 50-Day Moving Average | 23.74 |
| 200-Day Moving Average | 23.68 |
| Relative Strength Index (RSI) | 45.52 |
| Average Volume (20 Days) | 1,616,178 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 9.09M |
| Short Previous Month | 8.28M |
| Short % of Shares Out | 5.28% |
| Short % of Float | 7.09% |
| Short Ratio (days to cover) | 3.94 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 1.14B |
| Gross Profit | 706.66M |
| Operating Income | 86.37M |
| Pretax Income | 121.37M |
| Net Income | 380.48M |
| EBITDA | 98.39M |
| EBIT | 86.37M |
| Earnings Per Share (EPS) | $2.21 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 956.47M |
| Total Debt | 73.85M |
| Net Cash | 882.62M |
| Net Cash Per Share | $5.12 |
| Equity (Book Value) | 1.31B |
| Book Value Per Share | 7.59 |
| Working Capital | 863.11M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 160.32M |
| Capital Expenditures | -14.69M |
| Depreciation & Amortization | 12.02M |
| Net Borrowing | n/a |
| Free Cash Flow | 145.63M |
| FCF Per Share | $0.85 |
Margins
| Measure | Value |
|---|
| Gross Margin | 62.06% |
| Operating Margin | 7.59% |
| Pretax Margin | 10.66% |
| Profit Margin | 33.42% |
| EBITDA Margin | 8.64% |
| EBIT Margin | 7.59% |
| FCF Margin | 12.79% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.98% |
| Shareholder Yield | n/a |
| Earnings Yield | 10.71% |
| FCF Yield | 4.10% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $30.53 |
| Price Target Difference | 48.28% |
| Analyst Consensus | Buy |
| Analyst Count | 20 |
| Revenue Growth Forecast (3Y) | 14.56% |
| EPS Growth Forecast (3Y) | 27.87% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 5.43 |
| Piotroski F-Score | 5 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |